Follicular cell-derived thyroid cancers are derived from the follicular cells in the thyroid gland, which secrete the iodine-containing thyroid hormones. Follicular cell-derived thyroid cancers can be classified into papillary thyroid cancer (80–85%), follicular thyroid cancer (10–15%), poorly differentiated thyroid cancer (<2%) and undifferentiated (anaplastic) thyroid cancer (<2%), and these have an excellent prognosis with the exception of undifferentiated thyroid cancer. The advent and expansion of advanced diagnostic techniques has driven and continues to drive the epidemic of occult papillary thyroid cancer, owing to overdiagnosis of clinically irrelevant nodules. This transformation of the thyroid cancer landscape at molecular and clinical levels calls for the modification of management strategies towards personalized medicine based on individual risk assessment to deliver the most effective but least aggressive treatment. In thyroid cancer surgery, for instance, injuries to structures outside the thyroid gland, such as the recurrent laryngeal nerve in 2–5% of surgeries or the parathyroid glands in 5–10% of surgeries, negatively affect quality of life more than loss of the expendable thyroid gland. Furthermore, the risks associated with radioiodine ablation may outweigh the risks of persistent or recurrent disease and disease-specific mortality. Improvement in the health-related quality of life of survivors of follicular cell-derived thyroid cancer, which is decreased despite the generally favourable outcome, hinges on early tumour detection and minimization of treatment-related sequelae. Future opportunities include more widespread adoption of molecular and clinical risk stratification and identification of actionable targets for individualized therapies.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
World Health Organization. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs (eds DeLellis, R. A., Lloyd, R. V., Heitz, P. U. & Eng, C. ) 49–80 (IARC Press, 2004).
Nikiforov, Y. E. & Nikiforova, M. N. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7, 569–580 (2011).
Jung, C. K. et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J. Clin. Endocrinol. Metab. 99, E276–E285 (2014). This study shows that the detection rate and the molecular profile of PTC have changed in the United States over the past three decades.
Albores-Saavedra, J., Henson, D. E., Glazer, E. & Schwartz, A. M. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype — papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr. Pathol. 18, 1–7 (2007).
Aschebrook-Kilfoy, B., Grogan, R. H., Ward, M. H., Kaplan, E. & Devesa, S. S. Follicular thyroid cancer incidence patterns in the United States, 1980–2009. Thyroid 23, 1015–1021 (2013).
Lise, M. et al. Changes in the incidence of thyroid cancer between 1991 and 2005 in Italy: a geographical analysis. Thyroid 22, 27–34 (2012).
Ahn, H. S., Kim, H. J. & Welch, G. H. Korea's thyroid cancer “epidemic” — screening and overdiagnosis. N. Engl. J. Med. 371, 1765–1767 (2014). This paper clearly shows that PTC has been increasingly diagnosed in the past two decades because of increased imaging; this may have resulted in surgeries for insignificant lesions without benefit to patients.
Davies, L. & Welch, H. G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295, 2164–2167 (2006).
Morris, L. G., Sikora, A. G., Tosteson, T. D. & Davies, L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 23, 885–891 (2013).
Davies, L. & Welch, H. G. Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head Neck Surg. 140, 317–322 (2014). By analysing nine surveillance, epidemiology and end results areas in the United States, the authors found that, during 1975–2009, the absolute increase in thyroid cancer in women was almost four-times greater than that of men, which is most likely due to higher diagnosis rates.
Hughes, D. T., Haymart, M. R., Miller, B. S., Gauger, P. G. & Doherty, G. M. The most commonly occurring papillary thyroid cancer in the United States is now a microcarinoma in a patient older than 45 years. Thyroid 21, 231–236 (2011).
Li, N., Du, X. L., Reitzel, L. R., Xu, L. & Sturgis, E. M. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008. Thyroid 23, 103–110 (2013).
Malone, M. K., Zagzag, J., Ogilvie, J. B., Patel, K. N. & Heller, K. S. Thyroid cancers detected by imaging are not necessarily small or early stage. Thyroid 24, 314–318 (2014).
Tuttle, R. M. et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341–1349 (2010).
Ricarte-Filho, J. et al. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid 22, 575–584 (2012).
International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence and mortality and prevalence worldwide in 2012. IARC [online], (2013).
United Nations Development Programme. Human Development Report 2013. The Rise of the South: Human Progress in a Diverse World (UNDP, 2013).
Vaccarella, S. et al. The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. Thyroid 25, 1127–1136 (2015). This study compares the number of new thyroid cancer cases by age group and time periods across countries to estimate the proportion of thyroid cancers that may be due to heightened surveillance of the thyroid gland.
La Vecchia, C. et al. Thyroid cancer mortality and incidence: a global overview. Int. J. Cancer 136, 2187–2195 (2014).
Neta, G. et al. A prospective study of medical diagnostic radiography and risk of thyroid cancer. Am. J. Epidemiol. 177, 800–809 (2013).
Franceschi, S. et al. The epidemiology of thyroid carcinoma. Crit. Rev. Oncog. 4, 25–52 (1993).
Rinaldi, S. et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int. J. Cancer 131, E1004–E1014 (2012).
Pellegriti, G. et al. Papillary thyroid cancer incidence in the volcanic area of Sicily. J. Natl Cancer Inst. 101, 1575–1583 (2009).
Brito, J. P., Morris, J. C. & Montori, V. M. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ 347, f4706 (2013).
Giordano, T. J. et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014). This study provides comprehensive molecular characterization of PTC using various genomic, epigenetic and proteomic approaches.
Cohen, Y. et al. BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst. 95, 625–627 (2003).
Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC–RAS–BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454–1457 (2003).
Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245–262 (2005).
Namba, H. et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 88, 4393–4397 (2003).
Nikiforova, M. N. et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399–5404 (2003).
Ricarte-Filho, J. C. et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69, 4885–4893 (2009).
Trovisco, V. et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 202, 247–251 (2004).
Hou, P., Liu, D. & Xing, M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 6, 377–379 (2007).
Basolo, F. et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab. 95, 4197–4205 (2010).
Ciampi, R. et al. Oncogenic AKAP9–BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 115, 94–101 (2005). This study reports on the association between mutation type (point mutations and chromosomal rearrangements) and cancer aetiology.
Namba, H., Rubin, S. A. & Fagin, J. A. Point mutations of Ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 4, 1474–1479 (1990).
Suarez, H. G. et al. Presence of mutations in all three Ras genes in human thyroid tumors. Oncogene 5, 565–570 (1990).
Karga, H. et al. Ras oncogene mutations in benign and malignant thyroid neoplasms. J. Clin. Endocrinol. Metab. 73, 832–836 (1991).
Manenti, G., Pilotti, S., Re, F. C., Della Porta, G. & Pierotti, M. A. Selective activation of Ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur. J. Cancer 30A, 987–993 (1994).
Ezzat, S., L. et al. Prevalence of activating Ras mutations in morphologically characterized thyroid nodules. Thyroid 6, 409–416 (1996).
Esapa, C. T., Johnson, S. J., Kendall-Taylor, P., Lennard, T. W. & Harris, P. E. Prevalence of Ras mutations in thyroid neoplasia. Clin. Endocrinol. (Oxf.) 50, 529–535 (1999).
Motoi, N., et al. Role of Ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol. Res. Pract. 196, 1–7 (2000).
Adeniran, A. J. et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 30, 216–222 (2006).
Santoro, M. et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 89, 1517–1522 (1992).
Jhiang, S. M. et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137, 375–378 (1996).
Santoro, M. et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12, 1821–1826 (1996).
Powell, D. J. Jr et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 58, 5523–5528 (1998).
Nikiforov, Y. E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 13, 3–16 (2002).
Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H. & Fagin, J. A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57, 1690–1694 (1997).
Fenton, C. L. et al. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J. Clin. Endocrinol. Metab. 85, 1170–1175 (2000).
Rabes, H. M. et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res. 6, 1093–1103 (2000).
Radice, P. et al. The human tropomyosin gene involved in the generation of the TRK oncogene maps to chromosome 1q31. Oncogene 6, 2145–2148 (1991).
Greco, A. et al. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 7, 237–242 (1992).
Miranda, C., Minoletti, F., Greco, A., Sozzi, G. & Pierotti, M. A. Refined localization of the human TPR gene to chromosome 1q25 by in situ hybridization. Genomics 23, 714–715 (1994).
Bongarzone, I. et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin. Cancer Res. 4, 223–228 (1998).
Leeman-Neill, R. J. et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer 120, 799–807 (2014).
Ricarte-Filho, J. C. et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J. Clin. Invest. 123, 4935–4944 (2013).
Kelly, L. M. et al. Identification of the transforming STRN–ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc. Natl Acad. Sci. USA 111, 4233–4238 (2014).
Kroll, T. G. et al. PAX8–PPARγ 1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289, 1357–1360 (2000).
Lui, W. O. et al. CREB3L2–PPARγ fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res. 68, 7156–7164 (2008).
Dwight, T. et al. Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88, 4440–4445 (2003).
French, C. A. et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am. J. Pathol. 162, 1053–1060 (2003).
Nikiforova, M. N. et al. RAS point mutations and PAX8–PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88, 2318–2326 (2003).
Armstrong, M. J. et al. PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid 24, 1369–1374 (2014).
Ito, T. et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 52, 1369–1371 (1992).
Donghi, R. et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 91, 1753–1760 (1993).
Fagin, J. A. et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 91, 179–184 (1993).
Dobashi, Y. et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn. Mol. Pathol. 3, 9–14 (1994).
Hou, P. et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 13, 1161–1170 (2007).
Santarpia, L., El-Naggar, A. K., Cote, G. J., Myers, J. N. & Sherman, S. I. Phosphatidylinositol 3-kinase/Akt and Ras/Raf–mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 93, 278–284 (2008).
Kunstman, J. W. et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum. Mol. Genet. 24, 2318–2329 (2015).
Landa, I. et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J. Clin. Endocrinol. Metab. 98, E1562–E1566 (2013).
Liu, T. et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33, 4978–4984 (2013).
Liu, X. et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.” Endocr. Relat. Cancer 20, 603–610 (2013).
Melo, M. et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 99, E754–E765 (2014).
Takahashi, K. et al. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol. Carcinog. 46, 242–248 (2007).
Hamatani, K. et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res. 68, 7176–7182 (2008).
Mizuno, T., Kyoizumi, S., Suzuki, T., Iwamoto, K. S. & Seyama, T. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 15, 1455–1460 (1997).
Mizuno, T. et al. Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 19, 438–443 (2000).
Caudill, C. M., Zhu, Z., Ciampi, R., Stringer, J. R. & Nikiforov, Y. E. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J. Clin. Endocrinol. Metab. 90, 2364–2369 (2005).
Nikiforova, M. N. et al. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290, 138–141 (2000).
Roccato, E. et al. Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res. 65, 2572–2576 (2005).
Gandhi, M., Medvedovic, M., Stringer, J. R. & Nikiforov, Y. E. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene 25, 2360–2366 (2006).
Richards, R. I. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet. 17, 339–345 (2001).
Buttel, I., Fechter, A. & Schwab, M. Common fragile sites and cancer: targeted cloning by insertional mutagenesis. Ann. NY Acad. Sci. 1028, 14–27 (2004).
Gandhi, M., Dillon, L. W., Pramanik, S., Nikiforov, Y. E. & Wang, Y. H. DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene 29, 2272–2280 (2010).
Guan, H. et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 94, 1612–1617 (2009).
Romei, C. et al. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J. Clin. Endocrinol. Metab. 97, E1758–E1765 (2012).
Huang, Y. et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl Acad. Sci. USA 98, 15044–15049 (2001).
Chevillard, S. et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin. Cancer Res. 10, 6586–6597 (2004).
Frattini, M. et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23, 7436–7440 (2004).
Mazzanti, C. et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 64, 2898–2903 (2004).
Giordano, T. J. et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24, 6646–6656 (2005).
Finley, D. J., Arora, N., Zhu, B., Gallagher, L. & Fahey, T. J. 3rd. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J. Clin. Endocrinol. Metab. 89, 3214–3223 (2004).
Nikiforova, M. N., Tseng, G. C., Steward, D., Diorio, D. & Nikiforov, Y. E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93, 1600–1608 (2008).
He, H. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA 102, 19075–19080 (2005).
Pallante, P. et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13, 497–508 (2006).
Mardente, S. et al. HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol. Rep. 28, 2285–2289 (2012).
Xing, M. Gene methylation in thyroid tumorigenesis. Endocrinology 148, 948–953 (2007).
Russo, D., Damante, G., Puxeddu, E., Durante, C. & Filetti, S. Epigenetics of thyroid cancer and novel therapeutic targets. J. Mol. Endocrinol. 46, R73–R81 (2011).
Fink, A., Tomlinson, G., Freeman, J. L., Rosen, I. B. & Asa, S. L. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod. Pathol. 9, 816–820 (1996).
Brignardello, E. et al. Ultrasound screening for thyroid carcinoma in childhood cancer survivors: a case series. J. Clin. Endocrinol. Metab. 93, 4840–4843 (2008).
Pacini, F. et al. Thyroid consequences of the Chernobyl nuclear accident. Acta Paediatr. Suppl. 88, 23–27 (1999).
Jacob, P., Kaiser, J. C. & Ulanovsky, A. Ultrasonography survey and thyroid cancer in the Fukushima Prefecture. Radiat. Environ. Biophys. 53, 391–401 (2014).
Michaelson, E. M. et al. Thyroid malignancies in survivors of Hodgkin lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 88, 636–641 (2014).
Herraiz, M. et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin. Gastroenterol. Hepatol. 5, 367–373 (2007).
Steinhagen, E. et al. The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin. Colorectal Cancer 11, 304–308 (2012).
Nose, V. Thyroid cancer of follicular cell origin in inherited tumor syndromes. Adv. Anatom. Pathol. 17, 428–436 (2010).
Richards, M. L. Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer. Surg. Oncol. Clin. N. Am. 18, 39–52 (2009).
Richards, M. L. Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid 20, 707–713 (2010).
Navas-Carrillo, D., Rios, A., Rodriguez, J. M., Parrilla, P. & Orenes-Pinero, E. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings. Biochim. Biophys. Acta 1846, 468–476 (2014).
Clark, O. H. Familial non medullary thyroid cancer. Acta Chirurgica Austriaca 34, 292 (2002).
Nose, V. Familial follicular cell tumors: classification and morphological characteristics. Endocr. Pathol. 21, 219–226 (2010).
Oakley, G. M. et al. Increased melanoma risk in individuals with papillary thyroid carcinoma. JAMA Otolaryngol. Head Neck Surg. 140, 423–427 (2014).
Sadowski, S. M. et al. Prospective screening in familial nonmedullary thyroid cancer. Surgery 154, 1194–1198 (2013).
Oakley, G. M., Curtin, K., Pimentel, R., Buchmann, L. & Hunt, J. Establishing a familial basis for papillary thyroid carcinoma using the Utah Population Database. JAMA Otolaryngol. Head Neck Surg. 139, 1171–1174 (2013).
Rosario, P. W. et al. Ultrasonographic screening for thyroid cancer in siblings of patients with apparently sporadic papillary carcinoma. Thyroid 22, 805–808 (2012).
Reiners, C. Radioactivity and thyroid cancer. Hormones 8, 185–191 (2009).
Nagataki, S. & Nystrom, E. Epidemiology and primary prevention of thyroid cancer. Thyroid 12, 889–896 (2002).
Memon, A., Godward, S., Williams, D., Siddique, I. & Al-Saleh, K. Dental x-rays and the risk of thyroid cancer: a case–control study. Acta Oncol. 49, 447–453 (2010).
Journy, N. et al. Predicted cancer risks induced by computed tomography examinations during childhood, by a quantitative risk assessment approach. Radiat. Environ. Biophys. 53, 39–54 (2014).
Inskip, P. D. Thyroid cancer after radiotherapy for childhood cancer. Med. Pediatr. Oncol. 36, 568–573 (2001).
Becker, D. V. & Zanzonico, P. Potassium iodide for thyroid blockade in a reactor accident: administrative policies that govern its use. Thyroid 7, 193–197 (1997).
Franic´, Z. Iodine prophylaxis and nuclear accidents. Arh. Hig. Rada Toksikol. 50, 223–233 (1999).
Braverman, E. R. et al. Managing terrorism or accidental nuclear errors, preparing for iodine-131 emergencies: a comprehensive review. Int. J. Environ. Res. Publ. Health 11, 7803–7804 (2014).
Huszno, B. et al. Influence of iodine deficiency and iodine prophylaxis on thyroid cancer histotypes and incidence in endemic goiter area. J. Endocrinol. Invest. 26, 71–76 (2003).
Clero, E. et al. Dietary iodine and thyroid cancer risk in French Polynesia: a case–control study. Thyroid 22, 422–429 (2012).
Liu, Z. T. & Lin, A. H. Dietary factors and thyroid cancer risk: a meta-analysis of observational studies. Nutr. Cancer 66, 1165–1178 (2014).
Minelli G., Conti, S., Manno, V., Olivieri, A. & Ascoli, V. The geographical pattern of thyroid cancer mortality between 1980 and 2009 in Italy. Thyroid 23, 1609–1618 (2013).
Woodruff, S. L., Arowolo, O. A., Akute, O. O., Afolabi, A. O. & Nwariaku, F. Global variation in the pattern of differentiated thyroid cancer. Am. J. Surg. 200, 462–466 (2010).
Gyory, F. et al. Differentiated thyroid cancer and outcome in iodine deficiency. Eur. J. Surg. Oncol. 30, 325–331 (2004).
Franceschi, S. Iodine intake and thyroid carcinoma: a potential risk factor. Exp. Clin. Endocrinol. Diabetes 106, S38–S44 (1998).
Knobel, M. & Medeiros-Neto, G. Relevance of iodine intake as a reputed predisposing factor for thyroid cancer. Arq. Bras. Endocrinol. Metabol. 51, 701–712 (2007).
Sehestedt, T., Knudsen, N., Perrild, H. & Johansen, C. Iodine intake and incidence of thyroid cancer in Denmark. Clin. Endocrinol. (Oxf.) 65, 229–233 (2006).
Xiao, Q., Park, Y., Hollenbeck, A. R. & Kitahara, C. M. Dietary flavonoid intake and thyroid cancer risk in the NIH-AARP diet and health study. Cancer Epidemiol. Biomarkers Prev. 23, 1102–1108 (2014).
Cho, Y. A. & Kim, J. Thyroid cancer risk and smoking status: a meta-analysis. Cancer Causes Control 25, 1187–1195 (2014).
Pazaitou-Panayiotou, K., Polyzos, S. A. & Mantzoros, C. S. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes. Rev. 14, 1006–1022 (2013).
Fincham, S. M., Ugnat, A. M., Hill, G. B., Kreiger, N. & Mao, Y. Is occupation a risk factor for thyroid cancer? J. Occup. Environ. Med. 42, 318–322 (2000).
Dickman, P. W., Holm, L. E., Lundell, G., Boice J. D. Jr & Hall, P. Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int. J. Cancer 106, 580–587 (2003).
Metzger, R. & Milas, M. Inherited cancer syndromes and the thyroid: an update. Curr. Opin. Oncol. 26, 51–61 (2014).
Milas, M. et al. Should patients with Cowden syndrome undergo prophylactic thyroidectomy? Surgery 152, 1201–1209 (2012).
Brito, J. P., Hay, I. D. & Morris, J. C. Low risk papillary thyroid cancer. BMJ 348, g3045 (2014).
Brito, J. P. & Davies, L. Is there really an increased incidence of thyroid cancer? Curr. Opin. Endocrinol. Diabetes Obes. 21, 405–408 (2014).
Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009). This paper contains the 2009 comprehensive recommendations from the American thyroid Association for diagnosis and management of thyroid nodules and cancer. However, the 2015 guidelines are in press, and readers should have access by the time of publication of the present review.
Kim, D. S. et al. Sonographic features of follicular variant papillary thyroid carcinomas in comparison with conventional papillary thyroid carcinomas. J. Ultrasound Med. 28, 1685–1692 (2009).
Vidal-Casariego, A. et al. Accuracy of ultrasound elastography in the diagnosis of thyroid cancer in a low-risk population. Exp. Clin. Endocrinol. Diabetes 120, 635–638 (2012).
Cibas, E. S., Ali, S. Z. & NCI Thyroid FNA State of the Science Conference. The Bethesda system for reporting thyroid cytopathology. Am. J. Clin. Pathol. 132, 658–665 (2009).
Brito, J. P., Castro, M. R., Dean, D. S., Fatourechi, V. & Stan, M. Survey of current approaches to non-diagnostic fine-needle aspiration from solid thyroid nodules. Endocrine 49, 745–751 (2015).
Porterfield, J. R. et al. Reliability of benign fine needle aspiration cytology of large thyroid nodules. Surgery 144, 963–968 (2008).
Richmond, B. K. et al. False-negative results with the Bethesda system of reporting thyroid cytopathology: predictors of malignancy in thyroid nodules classified as benign by cytopathologic evaluation. Am. Surg. 80, 811–816 (2014).
Castro, M. R. et al. Predictors of malignancy in patients with cytologically suspicious thyroid nodules. Thyroid 21, 1191–1198 (2011).
Nikiforov, Y. et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 120, 3627–3634 (2014).
Alexander, E. K. et al. Multicenter clinical experience with the Afirma gene expression classifier. J. Clin. Endocrinol. Metab. 99, 119–125 (2014).
McIver, B. et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytoologically indeterminate thyroid nodules. J. Clin. Endocrinol. Metab. 99, 4969–4977 (2014).
Thomusch, O. et al. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery 133, 180–185 (2003). References 152, 154 and 155 outline the newly developed molecular markers that are helpful in the management of indeterminate cytology obtained by FNA of thyroid nodules.
Dralle, H. et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 136, 1310–1322 (2004).
Giordano, D. et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid 22, 911–917 (2012). The rate of transient and permanent hypoparathyroidism was highest after bilateral central compartment node dissection compared to thyroidectomy with or without ipsilateral compartment dissection. The authors concluded that bilateral compartment dissection should be reserved for patients with node-positive PTC.
Dralle, H. & Machens, A. Surgical management of the lateral neck compartment for metastatic thyroid cancer. Curr. Opin. Oncol. 25, 20–26 (2013).
Machens, A., Holzhausen, H. J. & Dralle, H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 103, 2269–2273 (2005).
Londero, S. C. et al. Papillary thyroid microcarcinoma in Denmark 1996–2008: a national study of epidemiology and clinical significance. Thyroid 23, 1159–1164 (2013).
Mehanna, H. et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J. Clin. Endocrinol. Metab. 99, 2834–2843 (2014).
Arora, N. 3rd et al. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid 19, 473–477 (2009).
Hay, I. D. et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144, 980–987 (2008).
Mercante, G. et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 19, 707–716 (2009).
Lee, K. W., Cho, Y. J., Kim, J. G. & Lee, D. H. How many contralateral papillary thyroid carcinomas can be missed? World J. Surg. 37, 780–785 (2013).
Ito, Y. et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24, 27–34 (2014). This study shows that patients >60 years of age can be candidates for observation instead of surgery.
Park, Y. J. et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAFV600E mutation, clinicopathological features, and immunohistochemical findings. Head Neck 32, 38–45 (2010).
Niemeier, L. A. et al. A combined molecular–pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 118, 2069–2077 (2012).
Kuo, E. J., Goffredo, P., Sosa, J. A. & Roman, S. A. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid 23, 1305–1311 (2013).
Machens, A. & Dralle, H. Correlation between the number of lymph node metastases and lung metastasis in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 97, 4375–4382 (2012).
Vas Nunes, J. H. et al. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma. Thyroid 23, 811–816 (2013).
Cho, S. Y. et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery 157, 111–118 (2015).
Bardet, S. et al. Prognostic value of microscopic lymph node involvement in patients with papillary thyroid cancer. J. Clin. Endocrinol. Metab. 100, 132–140 (2015).
Conzo, G. et al. Impact of prophylactic central compartment neck dissection on locoregional recurrence of differentiated thyroid cancer in clinically node-negative patients: a retrospective study of a large clinical series. Surgery 155, 998–1005 (2014).
Wada, N. et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann. Surg. 237, 399–407 (2003).
Morris, L. G. T., Shaha, A. R., Tuttle, R. M., Sikora, A. G. & Ganly, I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 20, 153–158 (2010).
Regalbuto, C. et al. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid 21, 383–389 (2011).
Clain, J. B. et al. Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management. Thyroid 24, 951–957 (2014).
Ghossein, R. et al. Prognostic factors in papillary microcarcinoma with emphasis on histologic subtyping: a clinicopathologic study of 148 cases. Thyroid 24, 245–253 (2014).
Pacini, F. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006).
Dralle, H. et al. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch. Surg. 398, 347–375 (2013).
Sancho, J. J., Lennard, T. W., Paunovic, I., Triponez, F. & Sitges-Serra, A. Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch. Surg. 399, 155–163 (2014). Concerning the rate of postsurgical complications and lymph node recurrences, the authors concluded that routine central compartment dissection should be risk-stratified according to tumour size, the age of the patient, multifocality, the presence or absence of lymph node metastases and the experience of the surgeon.
Iacobone, M., Jansson, S., Barczyn´ski, M. & Goretzki, P. Multifocal papillary thyroid carcinoma — a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch. Surg. 399, 141–154 (2014).
Dutenhefner, S. E. et al. BRAF: a tool in the decision to perform elective neck dissection? Thyroid 23, 1541–1546 (2013).
Viola, D. et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma. Clinical implications derived from the first prospective randomized controlled single institution study. J. Clin. Endocrinol. Metab. 100, 1316–1324 (2015).
Niederer-Wüst, S. M. et al. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. Surgery 157, 119–125(2015).
van Heerden, J. A. et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 112, 1130–1136 (1992).
Dralle, H. & Machens, A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract. Res. Clin. Endocrinol. Metab. 22, 971–987 (2008).
Asari, R. et al. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann. Surg. 249, 1023–1031 (2009).
O'Neill, C. J. et al. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur. J. Surg. Oncol. 37, 181–185 (2011).
Dionigi, G. et al. Minimally invasive follicular thyroid cancer (MIFTC) — a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch. Surg. 399, 165–184 (2014). Hemithyroidectomy instead of total thyroidectomy is favoured for patients with exclusive capsular without vascular invasion, who are <45 years of age, with a tumour size of <40 mm and are without metastases.
Kushchayeva, Y., Duh, Q. Y., Kebebew, E. & Clark, O. H. Prognostic indications for Hürthle cell cancer. World J. Surg. 28, 1266–1270 (2004).
Bishop, J. A., Wu, G., Tufano, R. P. & Westra, W. H. Histological patterns of locoregional recurrence in Hürthle cell carcinoma of the thyroid gland. Thyroid 22, 690–694 (2012).
Volante, M. et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 100, 950–957 (2004).
Volante, M. et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am. J. Surg. Pathol. 31, 1256–1264 (2007).
Hiltzik, D. et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106, 1286–1295 (2006).
Ibrahimpasic, T. et al. Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986–2009 Memorial Sloan-Kettering Cancer Center experience. Thyroid 23, 997–1002 (2013).
Smallridge, R. C. et al. American thyroid guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22, 1104–1139 (2012).
Besic, N. et al. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur. J. Surg. Oncol. 27, 260–264 (2001).
Higashiyama, T. et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20, 7–14 (2010).
Ito, K. et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 34, 230–237 (2012).
Ross, D. S. et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19, 1043–1048 (2009).
Baudin, E. et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 83, 553–559 (1998).
Pacini, F. et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J. Clin. Endocrinol. Metab. 91, 926–932 (2006).
Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 620–629 (2015).
Mallick, U. et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674–1685 (2012).
Durante, C. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006).
Vaisman, F. et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin. Endocrinol. (Oxf.) 77, 132–138 (2012).
Maloof, F., Vickery, A. L. & Rapp, B. An evaluation of various factors influencing the treatment of metastatic thyroid carcinoma with I131. J. Clin. Endocrinol. Metab. 16, 1–27 (1956).
Ichikawa, Y., Saito, E., Abe, Y., Homma, M. & Muraki, T. Presence of TSH receptor in thyroid neoplasms. J. Clin. Endocrinol. Metab. 42, 395–398 (1976).
Pacini, F. et al. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin. Endocrinol. (Oxf.) 23, 405–411 (1985).
Pötter, E. et al. Western blot analysis of thyrotropin receptor expression in human thyroid tumors and correlation with TSH-binding. Biochem. Biophys. Res. Commun. 205, 361–367 (1994).
Sundram, F. et al. Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline. Thyroid 16, 461–469 (2006).
Pitoia, F. et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq. Bras. Endocrinol. Metab. 53, 884–897 (2009).
Pacini, F., Castagna, M. G., Brilli, L. & Pentheroudakis, G. Thyroid cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v214–v219 (2010).
Dunhill, T. P. The Lettsomian Lectures: “The surgery of the thyroid gland”. Trans. Med. Soc. Lond. 60, 234–282 (1937).
Balme, H. W. Metastatic carcinoma of the thyroid successfully treated with thyroxine. Lancet 266, 812–813 (1954).
McGriff, N. J. et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann. Med. 34, 554–564 (2002).
Biondi, B. & Cooper, D. S. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 20, 135–146 (2010).
Jonklaas, J. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16, 1229–1242 (2006).
Hovens, G. C. et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 92, 2610–2615 (2007).
Sugitani, I. et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J. Surg. 34, 1222–1231 (2010).
Carhill, A. A. et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS Registry analysis 1987–2012. J. Clin. Endocrinol. Metab. 100, 3270–3279 (2015).
Sugitani, I. & Fujimoto, Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J. Clin. Endocrinol. Metab. 95, 4576–4583 (2010).
Tuttle, R. M. et al. Thyroid carcinoma. J. Natl Compr. Canc. Netw. 8, 1228–1274 (2010).
Haugen, B. R. & Sherman, S. I. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr. Rev. 34, 439–455 (2013).
Brose, M. S. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 3 trial. Lancet 384, 319–328 (2014).
Blevins, D. P. et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 24, 918–922 (2014).
Leboulleux, S. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 2 trial. Lancet Oncol. 13, 897–905 (2012).
Carr, L. L. et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 16, 5260–5268 (2010).
Cabanillas, M. E., Brose, M. S., Holland, J., Ferguson, K. C. & Sherman, S. I. A Phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24, 1508–1514 (2014).
Bible, K. C. et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a Phase 2 consortium study. Lancet Oncol. 11, 962–972 (2010).
Schutz, F. A., Je, Y., Richards, C. J. & Choueiri, T. K. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J. Clin. Oncol. 30, 871–877 (2012).
Carhill, A. A. et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J. Clin. Endocrinol. Metab. 98, 31–42 (2013).
Brose, M. S. et al. An open-label, multi-center Phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer (ptc) positive for the BRAF V600 mutation and resistant to radioactive iodine (nct01286753, no25530). Eur. J. Cancer Abstr. 49, 28 (2013).
Kim, K. B. et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation. Thyroid 23, 1277–1283 (2013).
Dadu, R. et al. Efficacy and tolerability of vemurafenib in patients with BRAFV600E-positive papillary thyroid cancer: M. D. Anderson Cancer Center off label experience. J. Clin. Endocrinol. Metab. 100, E77–E81 (2015).
Falchook, G. S. et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25, 71–77 (2015).
Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 368, 623–632 (2013).
Rothenberg, S. M., McFadden, D. G., Palmer, E. L., Daniels, G. H. & Wirth, L. J. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin. Cancer Res. 21, 1028–1035 (2015).
Sherman, S. I. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.) 22, 464–468 (2010).
Shimaoka, K., Schoenfeld, D. A., DeWys, W. D., Creech, R. H. & DeConti, R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56, 2155–2160 (1985).
Mazzaferri, E. L. & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418–428 (1994).
Lundgren, C. I., Hall, P. & Dickman, P. W. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. Br. J. Surg. 94, 571–577 (2007).
Hay, I. D., McDougall, I. R. & Sisson, J. C. Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma. J. Nucl. Med. 49, 1395–1397 (2008).
Tagay, S. et al. Health-related quality of life, depression and anxiety in thyroid cancer patients. Qual. Life Res. 153, 755–763 (2005).
Dagan, T. et al. Quality of life of well-differentiated thyroid carcinoma patients. J. Laryngol. Otol. 118, 537–542 (2004).
Husson, O. et al. Health-related quality of life among thyroid cancer survivors: a systematic review. Clin. Endocrinol. (Oxf.) 75, 544–554 (2011). This article has outlined all of the HRQOL studies on thyroid cancer up to 2011.
Davids, T., Witterick, I. J., Eski, S., Walfish, P. G. & Freeman, J. L. Three-week thyroxine withdrawal: a thyroid-specific quality of life study. Laryngoscope 116, 250–253 (2006).
Dow, K. H., Ferrell, B. R. & Anello, C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7, 613–619 (1997).
Hoftijzer, H. et al. Quality of life in cured patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 93, 200–203 (2008).
Hirsch, D. et al. Illness perception in patients with differentiated epithelial cell thyroid cancer. Thyroid 19, 459–465 (2009).
Husson, O. et al. Fatigue among short- and long-term thyroid cancer survivors: results from the population-based PROFILES registry. Thyroid 23, 1247–1255 (2013).
Pelttari, H., Sintonen, H., Schalin-Jäntti, C. & Välimäki, M. J. Health-related quality of life in long-term follow-up of patients with cured TNM stage I or II differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 70, 493–497 (2009).
Schultz, P. N., Stava, C. & Vassilopoulou-Sellin, R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 25, 349–356 (2003).
Almeida, J., Vartanian, J. G. & Kowalski, L. P. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Arch. Otolaryngol. Head Neck 135, 342–346 (2009).
Botella-Carretero, J. I., Galan, J. M., Caballero, C., Sancho, J. & Escobar-Morreale, H. F. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr. Relat. Cancer 10, 601–610 (2003).
Eustatia-Rutten, C. F. A. et al. Quality of life in long-term exogenous subclinical hyperthyroidism and the effect of restoration of euthyroidism, a randomized controlled trial. Clin. Endocrinol. (Oxf.) 64, 284–291 (2006).
Husson, O. et al. Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry. Acta Oncol. 52, 249–258 (2013). This is a large study that used a thyroid cancer-specific HRQOL questionnaire with long-term data.
Tan, L. G., Nan, L., Thumboo, J., Sundram, F. & Tan, L. K. Health-related quality of life in thyroid cancer survivors. Laryngoscope 117, 507–510 (2007).
Malterling, R. R. et al. Differentiated thyroid cancer in a Swedish county — long-term results and quality of life. Acta Oncol. 49, 454–459 (2010).
Y.E.N. declares that he has received consulting fees from Quest Diagnostics. S.I.S. declares that he has received consulting fees from Bayer, Eisai and Exelixis. All other authors declare no competing interests.
About this article
Cite this article
Dralle, H., Machens, A., Basa, J. et al. Follicular cell-derived thyroid cancer. Nat Rev Dis Primers 1, 15077 (2015). https://doi.org/10.1038/nrdp.2015.77
Stromal interaction molecule 1 (STIM1) knock down attenuates invasion and proliferation and enhances the expression of thyroid-specific proteins in human follicular thyroid cancer cells
Cellular and Molecular Life Sciences (2021)
Cell Communication and Signaling (2020)
The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study
Updates in Surgery (2020)
Individualisierung des chirurgischen Vorgehens als Antwort auf Überdiagnostik und Übertherapie bei differenzierten Schilddrüsenkarzinomen
Der Pathologe (2019)
Scientific Reports (2016)